- Home
- CIM vs VRDN Comparison
CIM vs VRDN Comparison
Compare CIM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- VRDN
- Stock Information
- Founded
- CIM 2007
- VRDN 2006
- Country
- CIM United States
- VRDN United States
- Employees
- CIM N/A
- VRDN N/A
- Industry
- CIM Real Estate Investment Trusts
- VRDN Medical Specialities
- Sector
- CIM Real Estate
- VRDN Health Care
- Exchange
- CIM Nasdaq
- VRDN Nasdaq
- Market Cap
- CIM 1.1B
- VRDN 1.3B
- IPO Year
- CIM 2007
- VRDN N/A
- Fundamental
- Price
- CIM $13.43
- VRDN $17.41
- Analyst Decision
- CIM Buy
- VRDN Strong Buy
- Analyst Count
- CIM 3
- VRDN 11
- Target Price
- CIM $15.50
- VRDN $38.50
- AVG Volume (30 Days)
- CIM 446.3K
- VRDN 670.9K
- Earning Date
- CIM 08-06-2025
- VRDN 08-07-2025
- Dividend Yield
- CIM 11.01%
- VRDN N/A
- EPS Growth
- CIM N/A
- VRDN N/A
- EPS
- CIM 1.52
- VRDN N/A
- Revenue
- CIM $326,755,000.00
- VRDN $302,000.00
- Revenue This Year
- CIM $18.51
- VRDN N/A
- Revenue Next Year
- CIM $3.88
- VRDN $17,102.33
- P/E Ratio
- CIM $8.85
- VRDN N/A
- Revenue Growth
- CIM 11.90
- VRDN 4.86
- 52 Week Low
- CIM $9.85
- VRDN $9.90
- 52 Week High
- CIM $16.89
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- CIM 38.82
- VRDN 58.43
- Support Level
- CIM $13.82
- VRDN $16.65
- Resistance Level
- CIM $14.01
- VRDN $18.80
- Average True Range (ATR)
- CIM 0.24
- VRDN 0.81
- MACD
- CIM -0.08
- VRDN -0.03
- Stochastic Oscillator
- CIM 19.19
- VRDN 50.97
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).